个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Lu, S.[1] * ; Zhou, Q.[2] ; Liu, X.[3] ; Du, Y.[4] ; Fan, Y.[5] ; Cheng, Y.[6] ; Fang, J.[7] ; Lu, Y.[8] ; Huang, C.[9] ; Zhou, J.[10] ; Song, Y.[11] ; Wang, K.[12] ; Pan, H.[13] ; Yang, N.[14] ; Li, J.[15] ; Chen, G.[16] ; Chang, J.[17] ; Cui, J.[18] ; Liu, Z.[19] ; Bai, C.[20] ; Zhang, H.[21] ; Thurm, H.[22] ; Peltz, G.[22] ; Li, H.[23] ; Zhao, H.[23] ; Wu, Y.[2] ;
机构： [1]Shanghai Chest Hosp, Shanghai, Peoples R China [2]Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China [3]Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China [4]Anhui Med Univ, Affiliated Hosp 1, Hefei, Anhui, Peoples R China [5]Zhejiang Canc Hosp, Hangzhou, Peoples R China [6]Jilin Prov Canc Hosp, Changchun, Peoples R China [7]Beijing Canc Hosp, Beijing, Peoples R China [8]Sichuan Univ, West China Hosp, Chengdu, Peoples R China [9]Fujian Prov Oncol Hosp, Fuzhou, Peoples R China [10]Zhejiang Med Univ, Affiliated Hosp 1, Hangzhou, Peoples R China [11]Nanjing Gen Hosp, Nanjing Mil Command, Nanjing, Peoples R China [12]Zhejiang Univ, Coll Med, Affiliated Hosp 2, Hangzhou, Peoples R China [13]Zhejiang Univ, Coll Med, Sir Run Run Shaw Hosp, Hangzhou, Peoples R China [14]Hunan Prov Tumor Hosp, Changsha, Peoples R China [15]Sichuan Prov Canc Hosp, Chengdu, Peoples R China [16]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [17]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [18]First Hosp Jilin Univ, Changchun, Peoples R China [19]Capital Med Univ, Beijing Chest Hosp, Beijing, Peoples R China [20]Zhongshan Hosp, Shanghai, Peoples R China [21]Fourth Mil Med Univ, Tangdu Hosp, Xian, Peoples R China [22]Pfizer Inc, Boston, MA USA [23]Pfizer Inc, Shanghai, Peoples R China
出处：
ISSN：

关键词： ALK-positive NSCLC CNS metastases Lorlatinib

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2021]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Shanghai Chest Hosp, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Lu S.,Zhou Q.,Liu X.,et al.Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China[J].JOURNAL OF THORACIC ONCOLOGY.2021,16(10):S1088-S1089.
APA：
Lu, S.,Zhou, Q.,Liu, X.,Du, Y.,Fan, Y....&Wu, Y..(2021).Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China.JOURNAL OF THORACIC ONCOLOGY,16,(10)
MLA：
Lu, S.,et al."Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China".JOURNAL OF THORACIC ONCOLOGY 16..10(2021):S1088-S1089

相关文献

[1]Intracranial Efficacy of Lorlatinib via RANO-BM in ALK-Fusion NSCLC with CNS Metastases: A Retrospective, Multicenter Study [2]Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China [3]Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC [4]Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial [5]Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing. [6]Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC : Five-Year Update From the Phase 3 ALESIA Study [7]Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study [8]The Safety Profile and Preliminary Efficacy of Ceritinib 450mg with Food in Chinese ALK/ROS-1 Positive NSCLC Patients [9]Lorlatinib Continuation Study [10]Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC

资源点击量：52808 今日访问量：1 总访问量：4560 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号